American Biomanufacturing Summit 2025: Pioneering The Future Of Biomanufacturing And Life Sciences Innovation

San Francisco, CA –  The 11th Annual American Biomanufacturing Summit 2025, the premier event dedicated to the biomanufacturing and life sciences industries, is set to take place on April 15-16, 2025, in San Francisco, CA. This is a two-day event bringing together top biopharma industry leaders, innovators, and experts from across the globe to discuss emerging key trends, challenges, opportunities, and innovations in the biotechnology and biomanufacturing industry. Pharma Now is proud to be the official media partner for this landmark event, committed to delivering key insights and industry highlights to a global audience. 

Various leading companies like Abbvie, Amgen, Bayer, Biogen, GSK, Merck, and many more are the featured attendees of the event. The American Biomanufacturing Summit will showcase and discuss advancements in current trends, strategic insights, and best practices in key topics like AAV manufacturing, cell and gene therapy, capacity management, quality assurance, quality control, regulatory compliance, operational excellence, supply chain and logistics. Attendees will have the opportunity to explore engaging topics like bioprocessing, regenerative medicine, biologics manufacturing, and bio-innovation, engage with leaders, and participate in dynamic discussions that shape the future of biomanufacturing. 

Key Highlights of American Biomanufacturing Summit 2025

Manufacturing & Technology – The production of cell and gene therapies would benefit from flexible automated biomanufacturing facilities. Digital transformation while utilising automation technologies will accelerate the production of cell and gene therapies.

Quality & Compliance – Insights on developing advanced Quality Management Systems (QMS) with PAT technology, which improves testing quality while enhancing both CAPA systems and workforce methods for regulatory compliance.

Supply Chain & Logistics - Track-and-trace serialisation services should be combined with supply chain risk management strategies, and resilient operation methods should be adopted that scale biomanufacturing facilities.

Cell & Gene Therapy (CGT) – The development of Cell & Gene Therapy (CGT) requires organisations to scale manufacturing operations. At the same time, maintaining adherence to regulatory changes and advanced downstream purification systems are needed to satisfy market needs.

Additional Topics – Connect with solution providers specialising in AAV & gene therapy manufacturing, cGMP compliance, aseptic fill & finish, process optimisation, and cold chain logistics.

Nearly 200 executive leaders who represent biopharma and biotech sectors along with medical research facilities, developmental entities and regulatory teams will participate in this biomanufacturing event. The event will function as a knowledge-sharing centre that promotes collaborative projects which advance the biomanufacturing field.

As the official media partner, Pharma Now will play a vital role in ensuring that crucial event information reaches audiences by sharing exclusive insights on all new developments that stimulate industry innovation in the biomanufacturing sector. Join us at the American Biomanufacturing Summit 2025 and be part of the next wave of biomanufacturing innovation.

For more details and to register, visit the official website of the American Biomanufacturing Summit.